PledPharma’s first patient in Japan is worth SEK 49 million. And through its establishment at Sahlgrenska Science Park, the company wants to gain access to the expertise available in the Gothenburg region.
TEXT: ANNIKA ÅKERVALL FOTO: PLEDPHARMA
PledPharma are new members of Sahlgrenska Science Park and the company is in a new development phase. The inclusion of the first patient in Japan triggers a major payment from PledPharma’s partner Solasia Pharma.
This relates to the biotech company’s most advanced project, PledOx, which is being developed to reduce nerve damage in patients with colon and rectal cancer in connection with chemotherapy.
“A global phase III study was initiated in the fourth quarter of 2018. It has now also started in Asia, which is an important milestone,” says Nicklas Westerholm, CEO, PledPharma.
The collaboration with the Japanese pharmaceutical company, Solasia Pharma, began in November 2017 and concerns the development and commercialisation of the product in Japan, China, Hong Kong, Macao, South Korea and Taiwan.
READ MORE: Första asiatiska patienten ger Pledpharma 49 miljoner (in Swedish)
Important expertise in West Sweden
“We chose to place some of our operations at Sahlgrenska Science Park to attract expertise. This is a large area and, since we are working in the late phase of clinical drug research, it is natural that much of the expertise is in Gothenburg,” says Nicklas Westerholm, CEO at PledPharma.
Today, PledPharma has ten employees, as well as a number of consultants.
PledPharma is listed on the Nasdaq First North stock exchange.
The report, The Power of Coaction highlights more examples of how healthcare challenges are being tackled through passionate collaboration and by companies relevant on the global stage. Download the report here.
READ MORE: New innovation centre changes the cityshape
Interest in West Sweden is increasing, and more and more companies at Sahlgrenska Science Park have interests in Asia.
READ MORE: Medfield now has sights set on Asia
Facts: PledPharma is a biotech company with a unique and integrated drug development expertise focused on improving the treatment of serious illnesses with a large unmet medical need. The company has a proprietary and clinically proven technology, PLED (PyridoxyL EthylDiamine-based compounds). PledPharma is listed on the Nasdaq First North stock exchange.